CO5130028A1 - Prevencion de produccion de mucosidad en las vias respirato- rias al administrar sustancias antagonicas egfr - Google Patents

Prevencion de produccion de mucosidad en las vias respirato- rias al administrar sustancias antagonicas egfr

Info

Publication number
CO5130028A1
CO5130028A1 CO99052263A CO99052263A CO5130028A1 CO 5130028 A1 CO5130028 A1 CO 5130028A1 CO 99052263 A CO99052263 A CO 99052263A CO 99052263 A CO99052263 A CO 99052263A CO 5130028 A1 CO5130028 A1 CO 5130028A1
Authority
CO
Colombia
Prior art keywords
cup
proliferation
cells
egfr
hypersecretion
Prior art date
Application number
CO99052263A
Other languages
English (en)
Inventor
Jay A Nadel
Kiyoshi Takeyama
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of CO5130028A1 publication Critical patent/CO5130028A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Environmental Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Otolaryngology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método in vitro para seleccionar agentes candidatos para ser utilizados en composiciones farmacéuticas para prevenir la hipersecreción de mucosidad en las vías respiratorias, que comprende:(i) contactar un modelo in vitro de proliferación de células de copa con EGF o el equivalente funcional del mismo;(ii) contactar posteriormente el modelo in vitro con un agente candidato; y (iii) evaluar la proliferación de células de copa; en el que una disminución en la proliferación de células de copa indica el potencial terapéutico del agente.Un método in vivo para seleccionar agentes candidatos para ser utilizados en las composiciones farmacéuticas para prevenir la hipersecreción de mucosidad de las vías respiratorias que comprende: (i) crear un modelo animal de enfermedad pulmonaria de hipersecreción mediante el suministro de EGF-R; (ii) estimular al EGFR inducido con un ligante, para producir células de copa productoras de mucosa;(iii) estimular al EGFR inducido con un ligante, para producir células de copa productoras de mucosa;(iv) tratar con un agente candidato; y(v) evaluar la proliferación de células de copa o la secreción de mucosa;en el que la inhibición de proliferación de células de copa o secreción de mucosa indica el potencial terapéutico del agente candidato.
CO99052263A 1998-08-18 1999-08-18 Prevencion de produccion de mucosidad en las vias respirato- rias al administrar sustancias antagonicas egfr CO5130028A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9702398P 1998-08-18 1998-08-18

Publications (1)

Publication Number Publication Date
CO5130028A1 true CO5130028A1 (es) 2002-02-27

Family

ID=22260380

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99052263A CO5130028A1 (es) 1998-08-18 1999-08-18 Prevencion de produccion de mucosidad en las vias respirato- rias al administrar sustancias antagonicas egfr

Country Status (36)

Country Link
US (6) US6270747B1 (es)
EP (2) EP1119349B1 (es)
JP (2) JP2002539072A (es)
KR (1) KR100609646B1 (es)
CN (1) CN1184961C (es)
AR (1) AR020220A1 (es)
AT (1) ATE399541T1 (es)
AU (1) AU760766B2 (es)
BR (1) BR9912672A (es)
CA (1) CA2337422C (es)
CO (1) CO5130028A1 (es)
CY (1) CY1110370T1 (es)
CZ (1) CZ2001584A3 (es)
DE (1) DE69939022D1 (es)
DK (1) DK1119349T3 (es)
EA (1) EA004316B1 (es)
EE (1) EE200100097A (es)
ES (1) ES2310047T3 (es)
HK (1) HK1036219A1 (es)
HR (1) HRP20010119B1 (es)
HU (1) HUP0103894A3 (es)
ID (1) ID27345A (es)
IL (2) IL140855A0 (es)
MY (1) MY126490A (es)
NO (1) NO327000B1 (es)
NZ (1) NZ509271A (es)
PH (2) PH12010000215A1 (es)
PL (1) PL200940B1 (es)
PT (1) PT1119349E (es)
RS (1) RS50273B (es)
SI (1) SI1119349T1 (es)
SK (1) SK287805B6 (es)
TR (1) TR200100560T2 (es)
TW (1) TWI250019B (es)
UA (1) UA73722C2 (es)
WO (1) WO2000010588A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
EE200100097A (et) 1998-08-18 2002-06-17 The Regents Of The University Of California Hingamisteede lima tootmise tõkestamine EGF-R antagonistide manustamise teel
US20030149113A1 (en) * 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20030236300A1 (en) * 1999-10-27 2003-12-25 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
WO2002094318A1 (en) * 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
US6818446B2 (en) 2001-11-21 2004-11-16 The Regents Of The University Of California Compositions and methods for the analysis of mucin gene expression and identification of drugs having the ability to inhibit mucin gene expression
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
CA2483340A1 (en) * 2002-04-24 2003-11-06 Research Development Foundation Synergistic effects of nuclear transcription factor nf-.kappa.b inhibitors and anti-neoplastic agents
EP1523318A4 (en) * 2002-06-24 2007-07-04 Res Dev Foundation TREATMENT OF HUMAN MULTIPLE MYELOMA BY CURCUMIN
US20060241130A1 (en) * 2003-01-31 2006-10-26 Ehud Keinan Anti-inflammatory compositions and uses thereof
US7195899B1 (en) * 2003-03-14 2007-03-27 Florida State University Research Foundation, Inc. Cell-based biosensor for harmful airborne agents
EP1658061A2 (en) * 2003-08-26 2006-05-24 Research Development Foundation Aerosol delivery of curcumin
EP1694335A4 (en) 2003-08-26 2008-12-31 Res Dev Foundation OSTEOCLASTOGENESIS HEMMER AND ITS USES
US20060115523A1 (en) * 2004-12-01 2006-06-01 Konduri Kameswari S Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal
US11324698B2 (en) 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US8846079B1 (en) 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US20050096332A1 (en) * 2003-10-30 2005-05-05 Boehringer Ingelheim International Gmbh Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US7968575B2 (en) * 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
EP1753734A1 (en) * 2004-05-05 2007-02-21 Renopharm Ltd. Nitric oxide donors and uses thereof
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
US6998028B1 (en) * 2004-09-24 2006-02-14 Superpower, Inc. Methods for forming superconducting conductors
AU2005288519A1 (en) * 2004-09-27 2006-04-06 Technion Research & Development Foundation Ltd. Fatty acid modified polylysines as antimicrobial agents
US7915223B2 (en) * 2004-09-27 2011-03-29 Technion Research & Development Foundation Ltd. Antimicrobial agents
WO2006035706A1 (ja) * 2004-09-28 2006-04-06 Dainippon Ink And Chemicals, Inc. 薬効評価用動物、薬効評価用動物の慢性閉塞性肺疾患発症方法及びその動物を用いた薬効評価方法
JP4690158B2 (ja) * 2004-09-28 2011-06-01 スギ生物科学研究所株式会社 薬効評価用動物、薬効評価用動物の慢性閉塞性肺疾患発症方法及びその動物を用いた薬効評価方法
EP1933624A4 (en) * 2005-10-11 2009-09-16 Univ Washington COMPOSITIONS AND METHOD FOR THE TREATMENT OF HYPERSEKRETION OF RESPIRATORY WAYS
EP1921070A1 (de) * 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EA200901041A1 (ru) * 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
US20080293740A1 (en) * 2007-04-03 2008-11-27 Parion Sciences, Inc. Method of treating acid-sensing ion channel mediated pain, cough suppression, and central nervous system disorders
WO2008132737A1 (en) * 2007-04-30 2008-11-06 Technion Research & Development Foundation Ltd. Novel antimicrobial agents
WO2008132738A2 (en) * 2007-04-30 2008-11-06 Technion Research & Development Foundation Ltd. Anticancerous polymeric agents
WO2009098061A1 (de) * 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2733153C (en) * 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US8112365B2 (en) * 2008-12-19 2012-02-07 Foster Scott C System and method for online employment recruiting and evaluation
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
US8541382B2 (en) 2010-11-13 2013-09-24 Sirbal Ltd. Cardiac glycoside analogs in combination with emodin for cancer therapy
US8734859B1 (en) 2010-11-13 2014-05-27 Sirbal Ltd. Molecular combinations for cancer or other disease treatment
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
AU2012205791B2 (en) * 2011-01-10 2016-11-03 Invion, Ltd. Use of beta-adrenergic inverse agonists for smoking cessation
ES2703052T3 (es) 2012-08-03 2019-03-06 Cedars Sinai Medical Center Aislamiento de mutantes potenciadores del tráfico de proteína de entrega de fármacos
EP3027026A4 (en) 2013-07-31 2017-05-03 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2015082950A1 (en) 2013-12-02 2015-06-11 Sirbal Ltd. Herbal combinations for treatment of a skin condition
EP3328498B1 (en) 2015-07-29 2021-05-05 Sirbal Ltd. Medical kit comprising herbal combinations for treating psoriasis

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2932481A (en) * 1954-06-15 1960-04-12 Breer Bipod camera support
GB1242211A (en) * 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
FR2502627A1 (fr) * 1981-02-02 1982-10-01 Refarmed Sa Derives thioliques de l'erythromycine a activite therapeutique, procede de preparation et produits pharmaceutiques dans lesquels ils apparaissent
IT1173549B (it) * 1984-04-02 1987-06-24 Corvi Camillo Spa Estere dell'acido teofillin-7-acetico con il d,l-trans-sobrerolo avente attivita' mucosecretolitica-fluidificante e antibroncospastica, procedimento per la sua preparazione e sue composizioni farmaceutiche
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4904786A (en) * 1986-01-27 1990-02-27 American Home Products Corporation Quinoline compounds as antiallergic and antiinflammatory agents
US5089516A (en) * 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
AU4203789A (en) * 1988-09-28 1990-04-18 Upjohn Company, The 1,4-dihydrothionapthoquinone and heterocyclic congeners which inhibit lipoxygenase enzymes
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8904009D0 (en) 1989-02-22 1989-04-05 Celltech Ltd Vector
US5362755A (en) * 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
CA2082160C (en) * 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
US5116616A (en) * 1991-04-29 1992-05-26 Bio-Technology General Corp. Use of intratracheal administration of SOD to protect humans from lung injury due to hyperoxia and hyperventilation
DE4117078A1 (de) * 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
ES2284226T3 (es) 1991-07-02 2007-11-01 Nektar Therapeutics Dispositivo para proporcionar medicamentos en aerosol.
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
DE4310051A1 (de) 1992-04-11 1993-10-14 Byk Gulden Lomberg Chem Fab Weitere Verwendung substituierter Pyridazine
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
EP0659046A1 (en) * 1992-09-11 1995-06-28 The Regents of The University of Michigan Non-human animal with xenograft of on airway populated by human cells
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
WO1995006764A2 (en) 1993-09-03 1995-03-09 Vpi Holdings Ltd. Oligonucleotides with rna cleavage activity
DK0719412T3 (da) * 1993-09-13 1999-07-19 Merck Frosst Canada Inc Fremgangsmåde til måling af metaplastiske ændringer i slimsecernerende epithelceller
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
AU706417B2 (en) 1994-02-23 1998-06-17 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US20030114379A1 (en) * 1994-03-08 2003-06-19 Human Genome Sciences, Inc. Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (MPIF-1)
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
DK0817775T3 (da) 1995-03-30 2001-11-19 Pfizer Quinazolinderivater
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5932574A (en) 1995-04-27 1999-08-03 Zeneca Limited Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
SI0892789T2 (sl) * 1996-04-12 2010-03-31 Warner Lambert Co Ireverzibilni inhibitorji tirozin kinaz
AU727352B2 (en) * 1996-07-29 2000-12-14 Paringenix, Inc. Methods of treating asthma with o-desulfated heparin
SE9603725D0 (sv) 1996-10-11 1996-10-11 Astra Ab New teatment
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
AU1924699A (en) 1997-12-19 1999-07-12 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
DE69940808D1 (de) * 1998-03-04 2009-06-10 Bristol Myers Squibb Co Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
EE200100097A (et) 1998-08-18 2002-06-17 The Regents Of The University Of California Hingamisteede lima tootmise tõkestamine EGF-R antagonistide manustamise teel
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
ID29800A (id) 1999-02-27 2001-10-11 Boehringer Ingelheim Pharma Turunan-turunan 4-amino-kinazolin dan kinolin yang mempunyai efek inhibitor pada transduksi signal yang dimediasi oleh tirosin kinase
EP1226136B1 (en) * 1999-10-19 2004-12-29 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2403152C (en) 2000-04-08 2008-10-28 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6627634B2 (en) * 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them

Also Published As

Publication number Publication date
ID27345A (id) 2001-04-05
AU5676699A (en) 2000-03-14
HRP20010119B1 (en) 2008-05-31
DE69939022D1 (de) 2008-08-14
EA004316B1 (ru) 2004-02-26
HK1036219A1 (en) 2001-12-28
JP2009221212A (ja) 2009-10-01
IL140855A0 (en) 2002-02-10
NO20010749L (no) 2001-04-17
CA2337422C (en) 2010-11-02
EP1119349B1 (en) 2008-07-02
NZ509271A (en) 2003-10-31
US20080175797A1 (en) 2008-07-24
CZ2001584A3 (cs) 2002-06-12
US6566324B2 (en) 2003-05-20
EA200100136A1 (ru) 2001-10-22
US20030148990A1 (en) 2003-08-07
KR20010085412A (ko) 2001-09-07
MY126490A (en) 2006-10-31
AU760766B2 (en) 2003-05-22
RS50273B (sr) 2009-07-15
SK2162001A3 (en) 2002-08-06
CA2337422A1 (en) 2000-03-02
WO2000010588A9 (en) 2000-08-10
SK287805B6 (sk) 2011-10-04
PL200940B1 (pl) 2009-02-27
DK1119349T3 (da) 2008-10-13
CY1110370T1 (el) 2015-04-29
HUP0103894A3 (en) 2003-07-28
YU13201A (sh) 2005-07-19
US20010036919A1 (en) 2001-11-01
AR020220A1 (es) 2002-05-02
TWI250019B (en) 2006-03-01
PL351765A1 (en) 2003-06-16
JP2002539072A (ja) 2002-11-19
ES2310047T3 (es) 2008-12-16
PH12010000216A1 (en) 2015-07-27
IL140855A (en) 2011-02-28
NO20010749D0 (no) 2001-02-14
US6551989B2 (en) 2003-04-22
CN1184961C (zh) 2005-01-19
EP1119349A2 (en) 2001-08-01
WO2000010588A3 (en) 2001-05-25
PT1119349E (pt) 2008-10-14
US8071074B2 (en) 2011-12-06
US8048844B1 (en) 2011-11-01
TR200100560T2 (tr) 2002-05-21
US20010041178A1 (en) 2001-11-15
CN1354657A (zh) 2002-06-19
SI1119349T1 (sl) 2008-12-31
WO2000010588A2 (en) 2000-03-02
EP1970058A1 (en) 2008-09-17
HRP20010119A2 (en) 2002-02-28
US7358222B2 (en) 2008-04-15
PH12010000215A1 (en) 2015-07-27
KR100609646B1 (ko) 2006-08-04
HUP0103894A2 (hu) 2002-04-29
EE200100097A (et) 2002-06-17
ATE399541T1 (de) 2008-07-15
NO327000B1 (no) 2009-03-30
BR9912672A (pt) 2002-06-11
UA73722C2 (en) 2005-09-15
US6270747B1 (en) 2001-08-07

Similar Documents

Publication Publication Date Title
CO5130028A1 (es) Prevencion de produccion de mucosidad en las vias respirato- rias al administrar sustancias antagonicas egfr
DE50211204D1 (de) Cannabis extrakten pharmazeutische zusammensetzung
AR060931A1 (es) Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion
NO20073337L (no) Fremgangsmater for behandling av andedrettssykdommer ved anvendelse av antagonister av interleukin-1 reseptor type 1
EA200801698A1 (ru) Лекарственные композиции для применения в вагине
DE60115842D1 (de) Ventilanordnung
BR0311867A (pt) Forma de ministração adesiva a mucosa em forma de pelìcula e uso de um extrato ou de um óleo de cannabis para a produção de uma forma de ministração adesiva a mucosa em forma de pelìcula
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
SE9704833D0 (sv) New formulation
CR7152A (es) Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.
CR8850A (es) Composicion y metodo para tratar hemorroides y/o transtornos ano-rectales
ATE535237T1 (de) Verwendung von fts zur behandlung von malignen erkrankungen
RU2007135881A (ru) Композиция для снижения экссудации белков сыворотки
AR033024A1 (es) Conjugados de pregabalina-lactosa
HRP20080009T3 (en) Plant mucilage based lozenges against inflammatory diseases of the buccal and pharyngeal cavity
KR20240024175A (ko) 피부 신경섬유종의 치료에 사용하기 위한 니트록솔린
ES2145517T3 (es) Nuevos derivados monofuncionalizados de edta, dtpa y ttha y su utilizacion en el diagnostico y en la terapia medicinales.
KR20120085601A (ko) 백절유신탕 및 그 활성성분을 이용한 퇴행성관절염의 치료 방법
Pattanshetty et al. Cancer-related fibrosis: Prevention or treatment?–A descriptive review
CN103893297B (zh) 一种治疗鼻窦炎的中药膏
AR056831A1 (es) Metodo para el diagnostico y tratamiento de enfermedades cardiovasculares
CN106038665A (zh) 一种治疗慢性咽炎的中药组合物及制备方法
Bagdasaryan et al. Intranasal mucosal malignant melanoma
Takayama et al. Relationship between aspirin-induced small intestinal mucosal injury and oxidative stress
CN108685878A (zh) 一种治疗咽炎的贴剂